LENZ Therapeutics (LENZ) Stock: Buy, Sell, or Hold?
LENZ - LENZ Therapeutics, Inc. Common Stock
$3.22
0.03 (0.94%)
▲
5d:
-6.12%
30d:
-22.03%
90d:
-36.24%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When LENZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LENZ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LENZ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LENZ is currently trading at $3.22, which is considered oversold relative to its 30-day fair value range of $3.43 to $4.07.
Technical Outlook: Technically, LENZ is in a strong downtrend. Immediate support is located at $3.12, while resistance sits at $3.71.
Market Sentiment: LENZ scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $23.57 (+632.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LENZ is in a strong downtrend. Immediate support is located at $3.12, while resistance sits at $3.71.
Market Sentiment: LENZ scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $23.57 (+632.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.43 -
$4.07
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 632.0% below Wall St target ($23.57)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.43 -
$4.07
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.12
Resistance Level
$3.71
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.09
Wall Street Target
$23.57
(+632.0%)
Revenue Growth (YoY)
9.7%
Share & Embed Analysis
Last updated: October 22, 2026 9:32 AM ET
Data refreshes hourly during market hours. Next update: 10:32 AM
Data refreshes hourly during market hours. Next update: 10:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LENZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
